Cargando…
AB016. A double-blind, placebo-controlled, phase 2 trial of a novel toll-like receptor 7/8/9 antagonist (IMO-8400) in dermatomyositis
BACKGROUND: Dermatomyositis (DM) is an inflammatory disease of skin and muscle. Increased interferon (IFN) signaling is a prominent feature of DM, but the mechanisms leading to IFN production in DM are not understood. As toll-like receptor (TLR) 7/8/9 activation can lead to type I IFN production, TL...
Autores principales: | Kim, Yoo Jung, Schiopu, Elena, Dankó, Katalin, Mozaffar, Tahseen, Chunduru, Srinivas, Lees, Kirstin, Goyal, Namita, Sarazin, Jeffrey, Fiorentino, David F., Sarin, Kavita Y. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8033384/ http://dx.doi.org/10.21037/atm.2021.AB016 |
Ejemplares similares
-
AB015. Skin disease activity and autoantibody phenotype are major determinants of blood interferon signatures in dermatomyositis
por: Tabata, Mika, et al.
Publicado: (2021) -
Dermatomyositis autoantibodies: how can we maximize utility?
por: Hodgkinson, Luqman Mushila, et al.
Publicado: (2021) -
AB014. Developing classification criteria for skin-predominant dermatomyositis: assessing the methodology of the prospective validation study
por: Concha, Josef Symon S., et al.
Publicado: (2021) -
Dermatomyositis and malignancy: should all patients with dermatomyositis undergo malignancy screening?
por: Khanna, Urmi, et al.
Publicado: (2021) -
AB019. Response to tofacitinib in a case of refractory TIF-1 positive amyopathic dermatomyositis with arthritis
por: Jasmine, Sion Ward, et al.
Publicado: (2021)